Patient outcomes from lung cancer and diabetes mellitus: a matched case-control study

Nina J Karlin; Shailja B Amin; Matthew R Buras; Heidi E Kosiorek; Patricia M Verona; Curtiss B Cook

doi:10.4155/fsoa-2017-0081

Patient outcomes from lung cancer and diabetes mellitus: a matched case-control study

Future Sci OA. 2017 Sep 26;4(1):FSO248. doi: 10.4155/fsoa-2017-0081. eCollection 2018 Jan.

Authors

Nina J Karlin^{1

1}, Shailja B Amin^{1

1}, Matthew R Buras^{2

2}, Heidi E Kosiorek^{2

2}, Patricia M Verona^{3

3}, Curtiss B Cook^{4

5

4

5}

Affiliations

¹ Division of Hematology & Medical Oncology, Mayo Clinic Hospital, Phoenix, AZ, USA.
² Department of Biostatistics, Mayo Clinic, Scottsdale, AZ, USA.
³ Department of Information Technology, Mayo Clinic Hospital, Phoenix, AZ, USA.
⁴ Division of Endocrinology, Mayo Clinic, Scottsdale, AZ, USA.
⁵ Division of Preventive, Occupational & Aerospace Medicine, Mayo Clinic, Scottsdale, AZ, USA.

Abstract

Aim: This case-control study examined the impact of diabetes mellitus (DM) on survival in lung cancer patients and lung cancer on glycemic control in DM.

Materials & methods: Patients with a new lung cancer diagnosis and DM (n = 124) were matched to 124 lung cancer patients without DM. Laboratory results and DM and cancer therapies were obtained from electronic records.

Results: Five-year overall survival for lung cancer patients with and without DM was 20 versus 29% (p = .12). Glycemic control among DM patients did not change significantly with time.

Conclusion: DM does not cause adverse impact on lung cancer survival. Lung cancer does not affect glycemic control.

Keywords: diabetes; lung; malignancy; outcomes; survival.